Arthrex Eclipse™ Shoulder Prosthesis

This is an interventional treatment trial for Osteoarthritis Read More

Inclusion Criteria:

• The subject is > 21 years of age
• The subject has continued symptoms in target shoulder despite at least 3 months of other treatment modalities(e.g.: anti-inflammatory, physical therapy and steroid injections)
• The subject has a diagnosis in the target shoulder of one or more of the following:

osteoarthritis, avascular necrosis, post-traumatic arthritis, or rheumatoid arthritis.

• The subject presents with pain and functional impairment in the index shoulder, measured by an Adjusted Constant Score of ≤50. Note: The Adjusted Constant Score will be calculated from the raw Constant Score to establish patient eligibility.
• The subject is willing to receive implantation of the Arthrex™ Shoulder Prosthesis or Univers™ II Shoulder Prosthesis.
• The subject must be physically and mentally willing and able to comply with all study procedures (including follow-up visits and radiographic assessments) until the conclusion of the study.
• The subject has been informed of the nature of the study and provided written consent as approved by the sites local Institutional Review Board or Ethic Review Board.

Exclusion Criteria:

• The subject is likely a candidate for hemi-humeral arthroplasty (i.e.: Avascular Necrosis of the humeral head without glenoid involvement (Stages 0-3): Rotator Cuff Deficient Shoulder: Glenoid Bone deficiency/deformity that precludes glenoid replacement (Walch Type B2 or C) or Fractures of the Proximal Humerus, without Glenoid involvement.
• The subject has immature bone as defined by the absence of cancellous bone patterning, a mature, thick cortex, and stress lines within the cancellous bone.
• The subject has obvious defects in bone quality, such as cysts or lesions, in the humeral head of the target shoulder, as demonstrated by radiographic evaluation.
• The subject has a target shoulder a rotator cuff that is not intact and not reconstructible.
• The subject has Irreducible 3- and 4- part proximal humeral fractures of the target shoulder.
• The subject has documented history of foreign-body sensitivity.
• Subject with positive pregnancy test, or lactating, or intends to become pregnant during treatment period
• The subject has history of Schizophrenia, Bipolar Disorder and/or Major Depressive Disorder as defined by DSM IV.
• The subject is skeletally immature demonstrated radiographically by incomplete closure of proximal humeral epiphyses.
• The subject is at high risk for poor healing or confounding outcomes [(i.e.: clinically significant renal, hepatic, cardiac hematologic disease or endocrine disease)]
• The subject is on immune-stimulating or immunosuppressive agents
• The subject has co-morbidity that reduces life expectancy < 36 month.
• The subject seeking or receiving workman's compensation for shoulder injury,
• The subject is > 350 lbs.
• The subject engaged in heavy labor (e.g. repetitive lifting in the excess of more than 50 lbs.)
• The subject has had surgery in the affected shoulder in the last 12 months (with the exception of diagnostic arthroscopy without reconstruction or repair procedures)
• The subject is engaged in active sports participation. (e.g. weight lifting involving upper extremities or involved in contact sports)
• The subject is taking medications known to potentially interfere with bone/soft tissue healing (e.g. steroids with the exception of topical and/or inhalers)
• The subject is a prisoners or wards of the state
• The subject has a history of alcohol and/or substance abuse as defined by DSM IV (Diagnostic and Statistical Manual Diploma in Social Medicine)
• The subject has an active or chronic infection, either systemic or local.
• The subject has pathologic fractures of the affected shoulder
• The subject has acute trauma of the affected shoulder
• The subject has osteoporosis defined as a bone density T score of < or = -2.5. (A screening Questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation) and MORES (Male Osteoporosis Risk Estimation Score), will be used to screen patients who require a DEXA (dual energy x-ray absorptiometry) bone mineral density measurement.